Infineon Technologies AG

  • WKN: 623100
  • ISIN: DE0006231004
  • Land: Deutschland

Nachricht vom 25.11.2021 | 17:45

Infineon Technologies AG: Supervisory Board appoints Jochen Hanebeck as successor to Dr. Reinhard Ploss as CEO of Infineon

Infineon Technologies AG / Key word(s): Personnel
Infineon Technologies AG: Supervisory Board appoints Jochen Hanebeck as successor to Dr. Reinhard Ploss as CEO of Infineon

25-Nov-2021 / 17:45 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Neubiberg, Germany, 25 November 2021 - Jochen Hanebeck is going to take over as the new Chief Executive Officer of Infineon Technologies AG on 1 April 2022. This was decided today by the Supervisory Board. Hanebeck was reappointed for five years, his contract runs until 31 March 2027. He has been a member of the Executive Board and Chief Operations Officer since 2016. He succeeds Dr. Reinhard Ploss, who is leading the company as CEO since 2012.




Contact:
Alexander Foltin, Investor Relations, phone: +49 89 234-23766, fax: +49 89 234-9559847

25-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021